Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18023350 | 0.83 | FBP1 (0.56) | FBP1CA2CA12CA3CA6 | |
| SCHEMBL13267511 | 0.83 | FBP1 (0.56) | FBP1CA2CA12CA3CA6 | |
| SCHEMBL566441 | 0.79 | FBP1 (0.57) | FBP1CA2CA12CA3CA6 | |
| SCHEMBL566440 | 0.79 | FBP1 (0.57) | FBP1CA2CA12CA3CA6 | |
| SCHEMBL6824611 | 0.77 | KMT2A (0.77) | FBP1CA2CA12CA3CA6 | |
| SCHEMBL26604322 | 0.77 | FBP1 (0.50) | FBP1CA2CA12CA3CA6 | |
| SCHEMBL14198043 | 0.77 | FBP1 (0.59) | FBP1CA2CA12CA3CA6 | |
| SCHEMBL28465290 | 0.77 | ALDH1A1 (0.58) | FBP1CA2CA12CA3CA6 | |
| SCHEMBL3246531 | 0.75 | AKR1C3 (0.62) | FBP1ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL2439472 | 0.75 | FBP1 (0.57) | FBP1CA2ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615525-B1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| CN-118702593-A | Preparation method and application of bisacylhydrazone derivative | 沈阳药科大学 | 2024-09-27 | — | — | CN | disclosed |
| US-11884656-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2024-01-30 | — | — | US | disclosed |
| EP-4276087-A1 | BETA-ELEMENE VINYLATION COUPLED DERIVATIVE, AND PREPARATION THEREOF AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG | Hangzhou Normal University (CN) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023160035-A1 | β-ELEMENE VINYLATION COUPLED DERIVATIVE, AND PREPARATION THEREOF AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG | 杭州师范大学 | 2023-08-31 | — | — | WO | disclosed |
| CN-110573503-B | Pyrrole derivatives as PLK1 inhibitors | 圣提内尔肿瘤学有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| EP-3615525-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2020-03-04 | — | — | EP | disclosed |
| CN-110573503-A | pyrrole derivatives as PLK1 inhibitors | 圣提内尔肿瘤学有限公司 | 2019-12-13 | — | — | CN | disclosed |
| WO-2018197714-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884656-B2 | Pyrrole derivatives as PLK1 inhibitors | PLK1, CDK1, AURKC | FBP1 2320/4885CA2 1493/4885CA12 3652/4885 |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | FBP1 2413/4885CA2 1567/4885CA12 3736/4885 |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | FBP1 2320/4885CA2 1493/4885CA12 3652/4885 |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | PLK1, CDK1, AURKC | FBP1 2413/4885CA2 1567/4885CA12 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.